

## SGX942 – Key References

### Presentations:

Donini O. Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease. Presentation at the 2017 Drug Discovery and Therapy World Congress Meeting. **July 10-13, 2017.**



[View PDF file online](#)  
[View presentation on YouTube](#)

Donini O. Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease – “Supercharging existing and new antibiotic therapies”. Presentation at the 2017 Superbugs & Superdrugs Meeting. **March 20-21, 2017.**



[View PDF file online](#)  
[View presentation on YouTube](#)

Donini O, Straube R. SGX942 Reduces the Duration of Severe Oral Mucositis. Presentation at 2016 Multinational Association for Supportive Care in Cancer Conference. **June 23-25, 2016**



[View PDF file online](#)

Donini O, Morici L. Innate Defense Regulators as Treatment for Melioidosis. Presentation at 2015 ASM Biodefense and Emerging Diseases Research Meeting. **February 9-11, 2015.**



[View PDF file online](#)

Donini, O. Dusquetide: Innate Defense Regulation as a Novel Approach to Antibiotic-Resistant Infection. Presentation at BARDA TechWatch Meeting. **August 2016.**



[View PDF file online](#)

### Papers:

Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. *Biotech Reports*. 2017; 15:24-26.



[View PDF file online](#)

Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. *J Biotech* **2016**; 239: 115-125.



[View link online](#)

North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici L, Finlay BB, Schaber CJ, Straube R, Donini O. A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. *J Biotech* **2016**; 226: 24-34.

 [View link online](#)

Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A, Wang A, Lee K, Doria S, Hamill P, Yu JJ, Li Y, Donini O, Guarna MM, Finlay BF, North JR, Hancock REW. An anti-infective peptide that selectively modulates the innate immune response. *Nat Biotechnol* **2007**;25: 465-72.

 [View link online](#)

Yu HB, Kielczewska A, Rozek A, Takenaka S, Li Y, Thorson L, et al. Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide. *J Biol Chem*. **2009**;284,36007-11.

 [View link online](#)

Aita V et al. Cloning and genomic organization of Beclin-1, a candidate tumor suppressor gene on chromosome 17q21. *Genomics*. **1999**. 59:59-65.

Alterovitz G, Tuthill C, Rios I, Modelska K, Sonis S. 2011. Personalized medicine for mucositis: Bayesian networks identify unique gene clusters, which predict the response to gamma-D-glutamyl-L-tryptophan (SCV-07) for the attenuation of chemoradiation-induced OM. *Oral Oncol*. **2011**;47:951-5.

Athman R, Philpott D. Innate immunity via Toll-like receptors and Nod proteins. *Curr Opin Microbiol*. **2004**;7,25-32.

Beutler B, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. *J Leukoc Biol*. **2003**;74,479-85.

Beutler B. Innate immunity: an overview. *Mol Immunol*. **2004**;40,845-59.

Doyle SL, O'Neill LA. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. *Biochem Pharmacol*. **2006**;72,1102-13.

Dupont N, Lacas-Gervais S, Bertout J, Paz I, Freche B, Van Nhieu GT, et al. Shigella phagocytic vacuolar membrane remnants participate in the cellular response to pathogen invasion and are regulated by autophagy. *Cell Host Microbe*. **2009**;6,137-49

Elting L et al. 2008 Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. *Cancer*, **2008**;113(10), 2704-13.

Finlay BB, Hancock RE. Can innate immunity be enhanced to treat microbial infections? *Nat Rev Microbiol* **2004**;2: 497-504.

Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. *Nature*. **2007**;447,972-8

Into T, Inomata M, Niida S, Murakami Y, Shibata K. Regulation of MyD88 Aggregation and the MyD88-dependent Signaling Pathway by Sequestosome-1 and Histone Deacetylase 6. *J Biol Chem*. **2010**;285(46),35759-35769

Janeway CA, Jr., Medzhitov R. Innate immune recognition. *Annu Rev Immunol.* **2002**;20,197-216.

Kim JY, Ozato K. The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by inhibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-kappaB activity. *J Immunol.* **2009**;182,2131-40

Matzinger, P. The Danger Model : A renewed sense of self. *Science.* **2002**; 296(5566), 301-305

Moscat J, Diaz-Meco MT, Wooten MW. Signal integration and diversification through the p62 scaffold protein. *Trends Biochem Sci.* **2007**;32,95-100.

Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. *Cell* **2009**; 137(6),1001-4.

Nonzee NJ, Dandade NA, Markossian T, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, Bennett CL. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis. *Cancer.* **2008**;113:1446–52.

Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. *Annals of Oncology* 22. **2011**; Supplement 6: vi78–vi84.

Rosenfeldt, M.T. and K. M. Ryan. The role of autophagy in tumour development and cancer therapy. *Exp Rev Mol Med* **2009**,11: e36.

Schwartzberg LS, Sonis ST, Walker MS, Weidner SM, Alterovitz G. Single Nucleotide Polymorphism (SNP) Bayesian networks (BNs) Predict Risk of Chemotherapy-Induced Side Effects in Patients with Breast Cancer Receiving Dose Dense (DD) Doxorubicin/Cyclophosphamide Plus Paclitaxel (AC+T). *Cancer Res.* **2012**;72 (24 Suppl): Abstract nr P1-15-12.

Sonis ST, Schwartzbert LS, Walker MS, Weidner S, Alterovitz G. 2013. Predicting risk of chemotherapy-induced side effects in patients with colon cancer with single-nucleotide polymorphism (SNP) Bayesian networks. *J Clin Oncol* **2013**;31 (4\_suppl): Abstract 344.

Seibenhener ML, Geetha T, Wooten MW. Sequestosome 1/p62--more than just a scaffold. *FEBS Lett.* **2007**;581,175-9

Sonis ST. A Biological Approach to Mucositis. *J Supp Onc.* **2004**; 2(1), 21-36.

Sonis ST. New thoughts on the initiation of mucositis. *Oral Dis.* **2010**;16,597-600.

Sonis ST, Antin JH, Alterovitz G. SNP-Based Bayesian networks define OM risk in patients receiving somatotoxic conditioning regimens for autologous hematopoietic stem cell transplantation. *Blood.* **2012**;120: Abstract 735.

Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, Mookanamparambil L, Ramoni M. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. *Oral Oncol.* **2007**;43:289-300.

Tosi MF. Innate immune responses to infection. *J Allergy Clin Immunol.* **2005**;116,241-9; quiz 50.

Yoshikawa Y, Ogawa M, Hain T, Yoshida M, Fukumatsu M, Kim M, et al. *Listeria monocytogenes* ActA-mediated escape from autophagic recognition. *Nat Cell Biol.* **2009**;11,1233-40

Zheng YT, Shahnazari S, Brech A, Lamark T, Johansen T, Brumell JH. The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. *J Immunol.* **2009**; 183,5909-16.

### Posters:

Donini O, Straube R. Host-Directed Innate Defense Regulators (IDRs) – Agnostic Therapy to Treat Bacterial Infections and Fight Resistance. Poster presented at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. **2018**.

 [View PDF file online](#)

Donini O, Behrens E, Haulenbeek A, Pullion C, Schaber C. An Innate Defense Regulator for the Treatment of Macrophage Activation Syndrome: Preclinical Studies in an Orphan Indication. Poster Presented at the National Organization for Rare Diseases (NORD) Rare Diseases and Orphan Products Breakthrough Summit. **2016**.

 [View PDF file online](#)

Donini O, Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Elder J. SGX942 Reduces the Duration of Severe Oral Mucositis. Poster presented at the 25<sup>th</sup> Multinational Association of Supportive Care in Cancer. **2016**.

 [View PDF file online](#)

Takenaka S, Rozek A, Kielczewska A, Thorson L, North JR, Finlay BB, Donini O. Innate Defense Regulators are a novel macrophage-mediated therapy to treat infectious and inflammatory diseases. Poster presentation at Keystone Symposium on The Macrophage: The intersection of Pathogenic & Protective Inflammation. **2010**.

 [View PDF file online](#)

Kielczewska A, Yu HB, Rozek A, Takenaka S, Li Y, Guarna MM, North JR, Foster LJ, Finlay BB, Donini O. Sequestosome-1 / p62 is the key intracellular target of innate defense regulator peptide. Poster presentation at Keystone Symposium on The Macrophage: The intersection of Pathogenic & Protective Inflammation. **2010**.

 [View PDF file online](#)

Donini O, Watkins BA, Palardy J, Opal S, Sonis S, Abrams MJ, North JR. Reduced Infection and Mucositis in Chemotherapy-Treated Animals Following Innate Defense Modulation Using a Novel Drug Candidate. 2010. *Blood* (ASH Annual Meeting Abstracts) **2010**; 116:3781.

 [View PDF file online](#)

Yu H, Kielczewska A, Rozek A, Takenaka S, Li Y, Guarna M, Thorson L, Hancock R, North J, Foster L, Donini O, Finlay B. SQSTM-1/p62: A Novel Therapeutic Target in Infectious and Inflammatory Disease. Poster Presentation at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. **2009**.

 [View PDF file online](#)